Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an update.
Recce Pharmaceuticals Ltd has reported significant progress in its clinical trials and strategic partnerships. The company has expanded its Phase 3 clinical trial sites in Indonesia and received additional approval for its Phase 2 trial, allowing more diabetic foot infection patients access to its R327G topical gel. This follows positive results in previous trials, indicating high efficacy. Additionally, Recce has entered into a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases, enhancing its research capabilities against biodefense pathogens. The company has also secured substantial funding through a capital raise and a non-dilutive financing agreement, strengthening its financial position.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a leading developer in the biotechnology industry, focusing on creating a new class of synthetic anti-infectives. The company is engaged in developing treatments for infectious diseases, with a market focus on innovative anti-infective solutions.
Average Trading Volume: 156,398
Technical Sentiment Signal: Hold
Current Market Cap: A$112.8M
Learn more about RCE stock on TipRanks’ Stock Analysis page.